These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22682947)

  • 1. The cost of screening for diabetes and intermediate hyperglycaemia.
    Colagiuri S
    Diabetes Res Clin Pract; 2012 Sep; 97(3):341-2. PubMed ID: 22682947
    [No Abstract]   [Full Text] [Related]  

  • 2. Finding undiagnosed type 2 diabetes: is it worth the effort?
    Engelgau MM; Narayan KM
    Eff Clin Pract; 2001; 4(6):281-3. PubMed ID: 11769302
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of type 2 diabetes screening: results from recently published studies.
    Icks A; Rathmann W; Haastert B; John J; Löwel H; Holle R; Giani G;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S167-71. PubMed ID: 16032536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening adults for pre-diabetes and diabetes may be cost-saving.
    Chatterjee R; Narayan KM; Lipscomb J; Phillips LS
    Diabetes Care; 2010 Jul; 33(7):1484-90. PubMed ID: 20587721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia.
    Wu EL; Kazzi NG; Lee JM
    JAMA Pediatr; 2013 Jan; 167(1):32-9. PubMed ID: 23403824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes in hemodialyzed patients when applying new diagnostic criteria.
    Elbert A; Schreier L; Galli C; Beresan H; Lopez G; Traversa M; Berg G
    J Ren Nutr; 2006 Oct; 16(4):300-3. PubMed ID: 17046613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
    Asakura T; Ito Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():237-41. PubMed ID: 15779378
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.
    Icks A; Haastert B; Gandjour A; John J; Löwel H; Holle R; Giani G; Rathmann W;
    Diabetes Care; 2004 Sep; 27(9):2120-8. PubMed ID: 15333472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
    Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
    Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-diabetes, dysglycaemia and early glucose intolerance and vascular health.
    Joshi SR; Karne R
    J Assoc Physicians India; 2007 Dec; 55():829-31. PubMed ID: 18405127
    [No Abstract]   [Full Text] [Related]  

  • 11. Frequency of 1-h post-load glucose ≥155 mg/dl among individuals with different glucose tolerance conditions.
    Fiorentino TV; Sesti F; Andreozzi F; Pedace E; Succurro E; Sciacqua A; Perticone F; Sesti G
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):439-41. PubMed ID: 27039961
    [No Abstract]   [Full Text] [Related]  

  • 12. Impaired glucose tolerance and the practical implications from a clinical perspective.
    Rahme K
    Int J Clin Pract; 2008 Jul; 62(7):988-9. PubMed ID: 18564271
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for diabetes, impaired glucose tolerance, and cardiovascular risk in primary care: a Northland, New Zealand pilot study.
    White B; Chamberlain N
    N Z Med J; 2009 May; 122(1295):28-37. PubMed ID: 19648984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in the Punjab Province of Pakistan.
    Shera AS; Basit A; Fawwad A; Hakeem R; Ahmedani MY; Hydrie MZ; Khwaja IA
    Prim Care Diabetes; 2010 Jul; 4(2):79-83. PubMed ID: 20149776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence and prognostic significance of pathological glucose metabolism in acute myocardial infarction].
    Egstrup M; Henriksen FL; Høfsten DE; Hangaard J; Egstrup K
    Ugeskr Laeger; 2008 Mar; 170(11):940-2. PubMed ID: 18397621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes, pre-diabetes and associated risks on Minnesota code-indicated major electrocardiogram abnormality among Chinese: a cross-sectional diabetic study in Fujian province, southeast China.
    Lin L; Chen G; Zou X; Zhao J; Zhu F; Tu M; Xu S; Lin W; Yang S; Zhang Y; Lin M; Chen N; Huang H; Liang J; Li L; Yao J
    Obes Rev; 2009 Jul; 10(4):420-30. PubMed ID: 19460110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral glucose tolerance test should be performed after stroke and transient ischemic attack.
    Lindsberg PJ; Tuomi T; Kaste M
    Int J Stroke; 2011 Aug; 6(4):317-20. PubMed ID: 21745342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis].
    Khammar A; Stremler N; Dubus JC; Gross G; Sarles J; Reynaud R
    Arch Pediatr; 2009 Dec; 16(12):1540-6. PubMed ID: 19854630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis.
    Khunti K; Gillies CL; Dallosso H; Brady EM; Gray LJ; Kilgallen G; Willis A; Zafar A; Davies MJ
    Diabetes Res Clin Pract; 2016 Aug; 118():12-20. PubMed ID: 27485852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting isolated postchallenge hyperglycaemia: a new approach; Tehran Lipid and Glucose Study (TLGS).
    Hosseinpanah F; Rambod M; Reza Ghaffari HR; Azizi F
    Diabet Med; 2006 Sep; 23(9):982-9. PubMed ID: 16922704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.